Fig. 2.

Download original image
Fig. 2. Comparison of success rates between second-line treat-ment with (IVIG+) and without concomitant IVIG (IVIG−) depicted as a function of age (younger than 8 years vs. 8 years and older). IVIG, intravenous immunoglobulin.
Clin Pediatr Hematol Oncol 2021;28:75-83
© 2021 Clin Pediatr Hematol Oncol